DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Saturday, 25 June 2016

Sreenivasa Reddy Mundla


Sreenivasa Reddy

 Sreenivasa Mundla Reddy

Managing Director at Sreeni Labs Private Limited

Sreeni Labs Private Limited
Road No:12, Plot No:24,25,26
  • IDA, Nacharam
    Hyderabad, 500076
    Telangana State, India

links
https://in.linkedin.com/in/sreenivasa-reddy-10b5876
https://www.facebook.com/sreenivasa.mundla
https://www.researchgate.net/profile/Sreenivasa_Mundla/info
mundlasr@hotmail.com
Ph:+91-9866092626

Sreenivasa Mundla Reddy




M. Sreenivasa Reddy obtained Ph.D from University of Hyderabad under the direction Prof Professor Goverdhan Mehta in 1992. From 1992-1994, he was a post doctoral fellow at University of Wisconsin in Professor Jame Cook's lab. From 1994 to 2000,  worked at Chemical process R&D at Procter & Gamble Pharmaceuticle (P&G). From 2001 to 2007 worked at Global Chemical Process R&D at Eli Lilly and Company in Indianapolis. 

In 2007  resigned to his  job and found Sreeni Labs based in Hyderabad and working with various global customers and solving various challenging synthesis problems.
 
The main strength of Sreeni Labs is in the design, development of a novel chemical route and its development into a robust process followed by production of quality product from 100 grams to 100s of kg scale.
 

They have helped number of customers by successfully developing highly economical simple chemistry routes to number of products that were made by Suzuki coupling. they are able to shorten the route by drastically reducing number of steps, avoiding use of palladium & expensive ligands. they always use readily available or easy to prepare starting materials in their design of synthetic routes.

Sreeni Labs is Looking for any potential opportunities where people need development of cost effective scalable routes followed by quick scale up to produce quality products in the pharmaceutical & specialty chemicals area. They have flexible business model that will be in sink with customers. One can test their abilities & capabilities by giving PO based projects

Experience







Founder & Managing Director

Sreeni Labs Private Limited
– Present (8 years 11 months)
Sreeni Labs Profile
Sreeni Labs Profile
View On SlideShare









Principal Research Scientist

Eli Lilly and Company
– (6 years 6 months)











Senior Research Scientist

Procter & Gamble
– (6 years 8 months)




Education











University of Hyderabad

Doctor of Philosophy (Ph.D.)




January 22, 2015 ·
With Sreenivasa Mundla, Narahara sastry, Ram Kishan Rao, Jagadeesh Bharatam, Jagadish Gunjur and Jagadish Bharatham.

 

 

 





See presentation below


Sreeni Labs Profile from Sreenivasa Reddy 
CLICK CURSOR TO VIEW




PUBLICATIONS





 Read at http://pharmacology.case.edu/department/faculty/primary/pages/Palczewski/articles/2015/Mol%20Pharmacol-2015-Zhang-477-91.pdf


Patents by Inventor Sreenivasa Reddy Mundla
  • TGF-? inhibitors
    Patent number: 7872020
    Abstract: The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro -4H-pyrrolo[1,2-b]pyrazole monohydrate.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: January 18, 2011
    Assignee: Eli Lilly and Company
    Inventor: Sreenivasa Reddy Mundla
  • TGF-BETA INHIBITORS
    Publication number: 20100120854
    Abstract: The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate.
    Type: Application
    Filed: June 29, 2006
    Publication date: May 13, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventor: Sreenivasa Reddy Mundla
  • Process for making 2-amino-2-imidazoline, guanidine and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives
    Patent number: 6066740
    Abstract: The present invention provides a process for making 2-amino-2-imidazoline, guanidine, and 2-amino-3,4,5,6-tetrahydroyrimidine derivatives by preparing the corresponding activated 2-thio-subsituted-2-derivative in a two-step, one-pot procedure and by further reacting yields this isolated derivative with the appropriate amine or its salts in the presence of a proton source. The present process allows for the preparation of 2-amino-2-imidazolines, quanidines, and 2-amino-3,4,5,6-tetrahydropyrimidines under reaction conditions that eliminate the need for lengthy, costly, or multiple low yielding steps, and highly toxic reactants. This process allows for improved yields and product purity and provides additional synthetic flexibility.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: May 23, 2000
    Assignee: The Procter & Gamble Company
    Inventors: Michael Selden Godlewski, Sean Rees Klopfenstein, Sreenivasa Reddy Mundla, William Lee Seibel, Randy Stuart Muth


TGF-β inhibitors
US 7872020 B2
 Sreenivasa Reddy Mundla
The present invention provides 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl) -5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate, i.e., Formula I.

Figure US07872020-20110118-C00002

 EXAMPLE 1 Preparation of 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl-5,6-dihydro-4H -pyrrolo[1,2-b]pyrazole monohydrate

Figure US07872020-20110118-C00008

  Galunisertib

1H NMR (CDCl3): δ=9.0 ppm (d, 4.4 Hz, 1H); 8.23-8.19 ppm (m, 2H); 8.315 ppm (dd, 1.9 Hz, 8.9 Hz, 1H); 7.455 ppm (d, 4.4 Hz, 1H); 7.364 ppm (t, 7.7 Hz, 1H); 7.086 ppm (d, 8.0 Hz, 1H); 6.969 ppm (d, 7.7 Hz, 1H); 6.022 ppm (m, 1H); 5.497 ppm (m, 1H); 4.419 ppm (t, 7.3 Hz, 2H); 2.999 ppm (m, 2H); 2.770 ppm (p, 7.2 Hz, 7.4 Hz, 2H); 2.306 ppm (s, 3H); 1.817 ppm (m, 2H). MS ES+: 370.2; Exact: 369.16



ABOVE MOLECULE IS
https://newdrugapprovals.org/2016/05/04/galunisertib/
Galunisertib
Phase III
LY-2157299
CAS No.700874-72-2


Sreeni labs









////////
Posted by at No comments:
Labels: ,

Hedieh Mehrtash




Hedieh Mehrtash

Fellow at National Cancer Institute (NCI)
hedieh.mehrtash@nih.gov
https://www.linkedin.com/in/hediehmehrtas
https://twitter.com/hediehmm
https://www.facebook.com/hedieh.mehrtash


 


 

 

Experience


Cancer Research Training Award Fellow

National Cancer Institute (NCI)
– Present (1 year)Center for Global Health

Non-Communicable Diseases Contributor

Global Health Middle East
– Present (2 years 4 months)
Global Health Middle East
Global Health Middle East

Team Leader

Global Oncology, Inc.
– (11 months)Greater Boston Area
www.globalonc.org

Graduate Teaching Assistant

Boston University School of Public Health
– (5 months)Department of Global Health
Course: Confronting Non-Communicable Diseases in the Developing World: The Burden, Costs, and Health Systems Challenges

Intern at NCD Synergies Network

Partners In Health
– (2 months)Boston, MA

Clinical Research Intern -Emergency Department

Beth Israel Deaconess Medical Center
– (9 months)Greater Boston Area
Analyzed the function of metabolites in critical illnesses such as cardiac arrest, sepsis, and traumatic brain injury and enrolled patients with inclusion criteria for the research.

Clinical Intern - Immunochemistry Laboratory

Hôpital Pitié-Salpêtrière
– (3 months)Paris Area, France

  

Hedieh is an MPH candidate at the Boston University School of Public Health, where she specialises in Global Health. Her interests lie in health system strengthening in the Middle East to address the rising tide of non-communicable diseases (NCDs), especially cancer. Given the lack of advocacy for public health and #NCDs in the region, Hedieh has been channeling her efforts through social media and blog posts on Global Health Middle East to draw attention to the various health system issues.

Education


Boston University

Bachelor of Science (BS), Human Physiology

Minor: French Language and Literature
Activities and Societies: Treasurer, President and VP of The BU Persian Club, Member of the Allocations Board, Member of the BU Arts Initiative Council

Honors & Awards

Merit Scholarship Recipient

Volunteer Experience & Causes


Volunteer

Make-A-Wish Foundation
– (3 years 9 months)Arts and Culture

Volunteer

Global Oncology, Inc.
– Present (2 years 8 months)Health



Publications


Childhood Cancers - A child health priority in MENA(Link)

Global Health Middle East
November 12, 2014

Improving Cancer Registries in the Middle East(Link)

Global Health Middle East
May 19, 2014

Obesity in the Middle East(Link)

Global Health Middle East
April 2, 2014

 Hedieh Mehrtash

 



//////////
Posted by at No comments:
Labels:

Friday, 24 June 2016

Saif Khan

Saif Khan







































Saif Khan





Saif Khan is an Associate Professor in the Department of Chemical and Biomolecular Engineering at the National University of Singapore, Singapore, and a Scientific Editor forReaction Chemistry & Engineering, helping to ensure that articles meet the stringent criteria required for publication in the journal. He works on the design and analysis of chemical reactors which perhaps go beyond the familiar – think reactions in bubbles, droplets and foams. His platform of choice is microfluidic systems, which allow the control of transport properties and non-equilibrium conditions for efficient, economical and sustainable chemical synthesis. His recent Green Chemistry paper is in this area:
Rapid nanoparticle-catalyzed hydrogenations in triphasic millireactors with facile catalyst recovery, Swee Kun Yap, Yuan Yuan, Lu Zheng, Wai Kuan Wong, Jiaguang Zhang, Ning Yan and Saif A. Khan, Green Chem., 2014, 16, 4654.
Dr Khan was a R. T. Haslam Presidential Fellow at MIT prior to moving to Singapore.\







////////////
Posted by at No comments:
Labels:

Donna Blackmond


Donna Blackmond


Donna Blackmond

Donna Blackmond is a Professor in the Department of Chemistry at The Scripps Research Institute, USA, and a Reaction Chemistry & Engineering Editorial Board member. Her research focusses on kinetic and mechanistic investigations of asymmetric catalytic reactions, probing the origin of biological homochirality or developing understanding of crucial synthetic pathways for pharmaceutical production, as in her recent Catalysis Science & Technology paper:
In 2013, Professor Blackmond was elected to the US National Academy of Engineering, and she is also an investigator in the Simons Collaboration on the Origins of Life.



/////
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)